Genomic Testing

Technician working with tissue samples

A genomic profile is more than just a test. Our assays provide biomarker information to help match patients to approved targeted therapies, immunotherapies, and clinical trials — giving doctors and patients powerful actionable insights for navigating cancer care.

Uncovering More Options for Each Unique Cancer

Each cancer is unique and each tumor can vary at the molecular level. A single genomic test can reveal alterations in DNA that drive cancer growth to help identify personalized treatment options based on a tumor’s unique genomic profile.

Next-Generation Sequencing (NGS) is used to analyze cancer specimens for all four classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements) known to be relevant in solid tumors, sarcomas, and hematologic malignancies.

Getting a Foundation Medicine Test

  1. Physician and patient discuss testing options together.
  2. Physician orders the appropriate test.
  3. Physician collects a tissue, blood, or bone marrow sample from patient.
  4. Physician sends sample to the Foundation Medicine laboratory.
  5. Physician receives online and printed results typically within 2 weeks from receipt of sample at Foundation Medicine.
  6. Physician and patient discuss results and potential treatment options.

Compare Foundation Tests

Our Diagnostic Portfolio

  • Foundation Medicine Symbol
  • Indications
  • Sample Type
  • Tumor Mutational Burden (TMB)*
  • Microsatellite instability (MSI)*
  • FoundationOne CDx™
  • NSCLC, CRC, Melanoma, Breast and Ovarian
  • FFPE
  • Yes
  • Yes
  • Details →
  • FoundationOne®
  • NSCLC, CRC, Melanoma, and other solid tumors
  • FFPE
  • Yes
  • Yes
  • Details →
  • FoundationACT®
  • Lung, GI, Breast, and other solid tumors
  • Peripheral Whole Blood
  • No
  • No
  • Details →
  • FoundationOne®Heme
  • Leukemias, lymphomas, or sarcomas
  • FFPE, Peripheral Blood, Bone Marrow Aspirate
  • Yes
  • Yes
  • Details →

Results & Reporting

Test results are provided directly to physicians in a report that highlights the genomic alterations in a patient’s cancer and includes information to help inform treatment decisions. Everything in the report is supported by up-to-date clinical findings and scientific research. Patients may request a copy of their report by contacting Client Services.

  1. Genomic Alterations
    Information about identified genomic alterations of all types and interpretation of results.
  2. Therapies
    List of available therapies relevant for the genomic alterations identified.
  3. Clinical Trials
    Clinical trials that the patient may be eligible for and guidance for the physician on identifying additional trials in public databases.
  4. Appendix
    Additional information such as the full list of genes assayed, variants of unknown significance, technical information, and references.
Genomic Testing Report

View a Sample FoundationOne® Report

Online Patient Reports for Physicians


Our secure online portal is free for physicians and provides online test results and the opportunity to share treatment experiences with colleagues.

Sign up today

Screenshot of patient reports (new design)

Support Services

A patient with cancer should not have to worry about the affordability of testing. That’s why we offer the FoundationAccess financial assistance program.

Learn More About Our Medicare Compliance Policy

A patient

Financial Assistance Program

Our financial assistance program provides patients with the opportunity for comprehensive genomic profiling, regardless of financial status. We also offer direct support and guidance during each step of the billing process.

More about Financial Assistance

A Foundation Medicine employee taking a phone call

Contact Us

We're committed to excellent service. If you have questions or need assistance, our client services team is on-hand to help.

Contact Client Services

Need More Details?

* Tumor Mutational Burden is a validated clinical marker associated with response to immunotherapy.